Helius Medical 2025 Q2 Earnings Sharp Net Loss Widens Despite EPS Improvement

Helius Medical (HSDT) reported its Q2 2025 earnings on August 14, 2025. The company narrowly improved its earnings per share but significantly widened its net loss, falling well short of profit expectations. While the EPS loss decreased year-over-year by 83.6%, the net loss more than quintupled from the prior year, signaling ongoing financial pressure.

Revenue
Helius Medical saw a dramatic 80.7% decline in total revenue to $43,000 in Q2 2025, compared to $171,000 in Q2 2024. Product sales, net, accounted for $33,000, while other revenue generated $10,000, reflecting a near-total drop in revenue across all segments.

Earnings/Net Income
The company narrowed its loss per share to $79.73 in Q2 2025, down from $485.30 in Q2 2024, an 83.6% improvement. However, the net loss expanded to $9.83 million, a 510.0% increase compared to the $1.61 million loss in the prior-year period, highlighting continued financial strain despite per-share improvement.

Price Action
Helius Medical’s stock has seen mixed performance in recent periods. While the stock gained 4.51% over the past week, it fell 21.92% month-to-date and declined slightly by 0.17% on the latest trading day.

Post Earnings Price Action Review
A strategy of buying Helius Medical shares following the earnings beat and selling after 30 days has performed poorly, yielding a -40.39% return over the past three years—significantly underperforming the benchmark by 86.86%. The strategy’s negative Sharpe ratio of -0.24 suggests high risk with little reward, while the maximum drawdown of 0% indicates it avoided losses in the tested period, but not meaningful gains.

CEO Commentary
Helius Medical CEO Brad L. Lander emphasized the company’s focus on expanding its neurostimulation therapy platform and strengthening its position in the rehabilitation industry. He highlighted the growing demand for non-invasive treatment solutions and the potential of the company’s NeuroRacer and Halo systems to drive future revenue. Despite ongoing R&D costs and regulatory challenges, Lander expressed cautious optimism about the long-term value of Helius’ technology. Strategic priorities include forming partnerships with healthcare providers and investing in clinical studies to support product validation, reinforcing the company’s commitment to innovation and patient outcomes.

Guidance
For Q2 2025, Helius Medical reported revenue of $33.0 million, an EPS of -$79.73, and a net loss of -$9.833 million. The company did not provide explicit guidance for future periods but indicated continued investment in R&D and market expansion as core strategic priorities. This guidance underscores a long-term growth strategy driven by product innovation and strategic partnerships, even amid short-term financial challenges.

Additional News
On August 14, 2025, the *Shanghai Daily* launched its online edition, offering subscribers access to real-time downloadable PDF files and unlimited access to current and archived content on ShanghaiDaily.com. Subscribers can also receive breaking news updates and newsletters, although print newspapers are not included. The digital subscription packages range from one month to 12 months, with combined print and digital options also available. Subscriptions are non-refundable and emphasize digital access as the primary offering for readers seeking up-to-date news in English.